Prosecution Insights
Last updated: April 19, 2026

Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd.

5 pending office actions

Portfolio Summary

5
Total Pending OAs
1
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18564796 USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME IN PREPARATION OF DRUGS FOR TREATING ADVANCED SOLID TUMORS PURDY, KYLE A 1611 Final Rejection Nov 28, 2023
18286592 USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME RZECZYCKI, PHILLIP MATTHEW 1625 Non-Final OA Oct 12, 2023
18269123 PHARMACEUTICAL COMPOSITION OF MULTI-TARGET PROTEIN KINASE INHIBITORS, AND USE THEREOF SHOWALTER, ALEXANDER KEITH 1629 Non-Final OA Jun 22, 2023
18266870 USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME PALLAY, MICHAEL B 1617 Non-Final OA Jun 13, 2023
18028960 A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF ROMERO, KRISTEN WANG 1624 Non-Final OA Mar 28, 2023

Managing Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month